BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33723523)

  • 1. The Case for Brachytherapy: Why It Deserves a Renaissance.
    Williams VM; Kahn JM; Thaker NG; Beriwal S; Nguyen PL; Arthur D; Petereit D; Dyer BA
    Adv Radiat Oncol; 2021; 6(2):100605. PubMed ID: 33723523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.
    Williams VM; Kahn JM; Harkenrider MM; Chino J; Chen J; Fang LC; Dunn EF; Fields E; Mayadev JS; Rengan R; Petereit D; Dyer BA
    Brachytherapy; 2020; 19(4):401-411. PubMed ID: 32359937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does brachytherapy have a role in the treatment of prostate cancer?
    Grimm PD; Blasko JC; Ragde H; Sylvester J; Clarke D
    Hematol Oncol Clin North Am; 1996 Jun; 10(3):653-73. PubMed ID: 8773503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
    Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
    Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.
    Ishiyama H; Satoh T; Kitano M; Tabata K; Komori S; Ikeda M; Soda I; Kurosaka S; Sekiguchi A; Kimura M; Kawakami S; Iwamura M; Hayakawa K
    J Radiat Res; 2014 May; 55(3):509-17. PubMed ID: 24222312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Delivery Costs for External Beam Radiation Therapy and Brachytherapy for Locally Advanced Cervical Cancer Using Time-Driven Activity-Based Costing.
    Bauer-Nilsen K; Hill C; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):88-94. PubMed ID: 29079120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
    Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cost-Effectiveness and Value Proposition of Brachytherapy.
    Vu CC; Jawad MS; Krauss DJ
    Semin Radiat Oncol; 2020 Jan; 30(1):87-93. PubMed ID: 31727304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern brachytherapy.
    Lukens JN; Gamez M; Hu K; Harrison LB
    Semin Oncol; 2014 Dec; 41(6):831-47. PubMed ID: 25499641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer.
    Spratt DE; Soni PD; McLaughlin PW; Merrick GS; Stock RG; Blasko JC; Zelefsky MJ
    Brachytherapy; 2017; 16(1):1-12. PubMed ID: 27771243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer.
    Tanaka N
    Prostate Int; 2023 Sep; 11(3):127-133. PubMed ID: 37745911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
    de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
    Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
    Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the best way to radiate the prostate in 2016?
    Moon DH; Efstathiou JA; Chen RC
    Urol Oncol; 2017 Feb; 35(2):59-68. PubMed ID: 27395453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
    Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
    Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?
    Safdieh J; Wong A; Weiner JP; Schwartz D; Schreiber D
    J Contemp Brachytherapy; 2016 Aug; 8(4):289-93. PubMed ID: 27648081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in gynecologic radiation oncology.
    Venkat PS; Parikh N; Beron P
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):38-42. PubMed ID: 30531605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.